The FDA green-lights Brainlab's mobile version of the TraumaCad surgical planning software for hip replacement procedures.
Brainlab said it won FDA clearance for a mobile version of its TraumaCad surgical planning software for hip replacement procedures.
The product, TraumaCad Mobile, will be marketed by Brainlab's Voyant Health unit. The application is compatible with Mac and PC web browsers plus iOS mobile devices.
The year-old collaboration between DePuy Synthes Spine and Brainlab now includes co-marketing a new product, in addition to continued development on surgical navigation and imaging devices.
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine said it's expanding its collaboration with Brainlab on surgical navigation and imaging devices, in addition to co-marketing Brainlab's Airo Mobile Intraoperative CT.
Jan Medical and Germany's Brainlab team up to land FDA clearances for Jan Medical's Nautilus NeuroWave device.
Jan Medical is partnering with software-driven medtech firm Brainlab to gain FDA clearances via 2 clinical trials, the companies announced.
As part of the collaboration, Brainlab will add a representative to Jan Medical's board, the companies said in a press release.
Mountain View, Calif.-based Jan Medical makes the the Nautilus NeuroWave, a portable, non-invasive brain sensing system designed to detect abnormal neurological conditions, including ischemic stroke, vasospasm, and concussion.
Johnson & Johnson's DePuy Synthes Spine division inks an integration pact with Brainlab for that company's imaging and navigation devices.
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine said it inked a deal with Brainlab to develop integrated surgical navigation and imaging devices.
Terumo warns users of false alarms in its heart-lung machines, which could result in disruptions to arterial blood flow or air bubble entrainment in the system.
Terumo Corp. (TYO:4543) warned users of its Advanced Perfusion System 1, Sarns Modular Perfusion System 8000 and Sarns Perfusion System 9000 of possible malfunctions related to the devices' air bubble detections systems.
The company has received "multiple reports" of false alarms generated by the air bubble warning system, although it's a "highly unlikely" malfunction.
Toshiba Medical announces the expiration of the initial tender offer period for outstanding shares of Vital Images.
Toshiba Medical Systems Corp. came one step closer the $273 million acquisition of Vital Images Inc. (NSDQ:VTAL) with the announcement that the initial tender offer period had expired.
A total of 11.9 million shares were tendered by expiration time, representing about 72 percent of Vital Images' outstanding common stock on a fully diluted basis.